China COVID-19 Vaccines Efficacy Inadequate? Hot Debate, Variant Worries Swirl
Mixing Vaccines And Newer Candidates To Help?
Executive Summary
China's regulators and spin doctors rush to remedy a comment from the nation’s top infectious disease official about the “not high” protection rate for its COVID-19 vaccines, amid debate over speedy development using mature technologies and doubts over protection in seniors. A slow roll-out is already presenting challenges to meeting an official 40% target.
You may also be interested in...
China Re-Infection Case Ignites Antibody Durability Debate
Amid a case of re-infection of a vaccinated healthcare worker in western China’s Xi’an city, and ongoing debate over domestic vaccines' efficacy, increasing attention is being paid in China to raising inoculation rates for COVID-19 and moving towards herd immunity.
Playing Catchup To US, China Ups COVID Vaccination Pressure
Facing a slow roll-out of COVID-19 vaccines, China is implementing more promotional measures and increasing the pressure on the public to get inoculated. Vaccine diplomacy efforts meanwhile are facing challenges.
AstraZeneca & Sputnik V COVID-19 Vaccine Combo To Enter Trial
There is growing in interest in boosting the first dose of a COVID-19 vaccine by administering a different vaccine as the second dose.